New business summary of BMDSys Optical investment

Executive Summary
Company: BMDSys Optical GmbH
Copy: No. 1/3
Date: October, 2014
Business plan: 3 business years plan
Founder (team): Volker Schall (CEO)
Dr. rer. nat. Gertrud Lembke (CTO)
Any information in this summary is confidential! Reproduction and copy ing requires
the agreement of De Micco & Friends Group!
1 www.demicco.ch

DISCLAIMER
The contents of this document are strictly confidential and were obtained inter alia from
publicly available information. This document (the “Concept, Structure & Investors
Presentation”) is a marketing document and not a regulatory document.
The sole purpose of this document is to assist the recipient in deciding whether to proceed with
a further investigation of an investment in BMDSys Optical GmbH, registered in Germany,
(“the “COMPANY”) and the "Proposed Transaction". This document does not purport to be all‐inclusive
or to contain all the information that a prospective interested party may desire to
evaluate the Proposed Transaction. This document has been prepared only for informational
purposes relating to the Proposed Transaction only.
Neither COMPANY nor its affiliates or representatives assumes any responsibility for the
independent verification of any of the information set forth in this document, or of any
additional evaluation material made available in connection with any further investigation of
the Proposed Transaction. Neither COMPANY nor its affiliates or representatives make any
express or implied representation or warranty as to the accuracy or completeness of the
information contained in, or for any omissions from, this document or any additional evaluation
material made available in connection with any further investigation of the Proposed
Transaction. In addition, COMPANY (on its own behalf and on behalf of its affiliates or
representatives) expressly disclaims any and all liability which may be based on such
information, errors therein or omissions there from.
Neither the receipt of this document by any person nor any information contained herein or
supplied herewith or subsequently communicated to any person in connection with the
Proposed Transaction is or is to be taken as constituting the giving of investment advice to any
such person. It is the responsibility of the recipient, before entering into any transaction, to
make its own appraisal of the Proposed Transaction, its advantages and risks, without relying
exclusively on the information that was provided to the recipient. If it deems necessary or
useful, the recipient may consult its own legal, tax, financial, accounting and other professional
advisors.
In furnishing this document, neither COMPANY nor its affiliates or representatives undertakes
any obligation to provide the recipient with access to any additional evaluation material.
COMPANY reserves the right to negotiate with one or more parties at any time and to enter into
a definitive agreement, without prior notice to the recipient or any other party. COMPANY
reserves the right to terminate, at any time, solicitation of indications of interest in the
Proposed Transaction or in the further participation in the investigation and proposal process by
any party.
Finally, COMPANY reserves the right to modify, at any time, any procedures relating to this
process without assigning any reason therefore. The information contained herein or made
available in connection with any further investigation of the Proposed Transaction is strictly
confidential. This document may not be photocopied, reproduced or distributed to any third
party at any time without the prior written consent of COMPANY. All communications, inquiries
and requests for information relating to these materials should be addressed to COMPANY.
COMPANY is the primary contact for the Proposed Transaction. Please direct all inquiries
regarding the Proposed Transaction to the representatives of COMPANY referred to below.
Interested parties will be required to sign a Non Disclosure Agreement (NDA) and send it, by
email and by post/hand, to the address below.
De Micco & Friends Group Corporation
(advisors, lawyers, auditors)
Switzerland
and
BMDSys Optical GmbH
Germany
2 www.demicco.ch

Contents
Overview
1. Executive summary
2. Product
3. Founder and management team
4. Market
5. Chances and risks
6. Financial planning
7. Offer for investors
3 www.demicco.ch

Overview
Project data
Entrepreneurs: Volker Schall and Dr. rer. nat. Gertrud Lembke
Planning: Continuation, development and marketing of an already developed
technology
Business location: Kurfürst‐Schönborn‐Straße 25, 56070 Koblenz, Germany
Legal form: GmbH (German Limited)
Company name: BMDSys Optical GmbH
Start of operation : previous company BMDSys GmbH 2005
Funding: Own funding and private equity
Future prospects: A unique product for risk stratification of sudden cardiac death (SCD)
has been developed that now has to be introduced worldwide.
5 www.demicco.ch

1.
Executive Summary
6 www.demicco.ch

1. Executive Summary
Product/Business model
In the industrialized countries heart diseases are cause of death number one!
Worldwide approx. 9 mio. people die per year because of sudden cardiac
death (SCD). In Germany there are 100,000 cases per year.
In approximately 80 % of all cases high frequent heart arrhythmias are
responsible. In principle every person can be in danger.
Sudden cardiac death (SCD) is in approx. 50 % of all cases the first
manifestation of a heart disease. The affected persons did not know about
their heart problem and thus could not take any preventive action.
The BMDSys Optical GmbH offers with a unique technical innovation a
solution for this problem!
7 www.demicco.ch

1. Executive Summary
Product/Business model
The diagnostic system developed by BMDSys Optical GmbH allows a
cardiologist to estimate the risk for sudden cardiac death within five
minutes based on the heart‘s magnetic signals.
The team of BMDSys Optical GmbH and the physicians accompanying
the clinical studies developed a technology that allows an individual risk
stratification, which saves many lives.
Thus, this innovation is not only a highly interesting investment, but of
high medical, clinical, sociological and economical relevance.
Investors can participate actively in the company and profit from the
future prospects.
8 www.demicco.ch

2.
Product/Service
9 www.demicco.ch

2. Product
2.1 Previous model
BMDSys Optical GmbH with its team is the follow-up of BMDSys
Production GmbH, which developed, produced and sold with the
same staff the first systems for MFI diagnostics.
With its research and development activities it achieved breaking
results and international acknowledgement. For the first time a
reliable system was available that could detect an enhanced risk
for sudden cardiac death.
Approx. 8 M. EURO were invested in the industrialization of
the first version.
10 www.demicco.ch

2. Product
2.1 Previous model
The systems of the first generation work perfectly and have
successfully been used in various hospitals.
However, the used technology requires liquid helium cooling, which
means an expense of approx. 700 to 900 K EURO during a mean
life cycle of 10 years. This generates high costs and reduces the
economical effectiveness of the systems in the clinical use.
This lack of economical efficiency of the previous model has
reduced the chances in sales in such a way that the former
company could not reach sustainable profit.
11 www.demicco.ch

2. Product
2.2 APOLLO CXS – the new sensor generation
Test finished
Prototype ready
More efficient
Low maintenance costs
ISO certification
Ready for market
Cheaper
New technology
Quicker production
Without cooling
Use in hospitals
Direct sales
Distributors
Sports organisations
Orders are placed!
Potential health insurances
High margins (50‐60 %)
First mover Technology
International demand
Mass production
Das team of BMDSys Optical
GmbH developed, based on the
original technology, a new
system that makes the helium
cooling superfluous. In this way
the operating costs are
importantly reduced.
Thus, the new systems are
highly interesting for any
hospital worldwide that offers
heart diagnostics. The prototype
developed under the label
APOLLO CXS is already
available. All tests have been
successful.
12 www.demicco.ch

2. Product
2.3 Projected development schedule
To distribute the APOLLO CXS with the new optical technology (OPM) in clinics and medical centers, a series production
has to be set up and financed. For the international market introduction a period of 1-2 years is scheduled. Already 8-12
months after project start, revenues are possible. The production time per system will be reduced in medium term to 4
weeks for being able to respond to the increasing demand. In 2 years an industrial mass production will become
necessary.
Development processes Phase 1 Phase 2 Phase 3 Phase 4 Phase 5 Phase 6
Development of the first system (helium)
Tests in hospitals and universities
First marketing national
Development APOLLO CXS (OPM)
Test APOLLO CXS
Start series production and marketing
Mass production, worldwide sales
Sales , marketing Development phases
International marketing
today mass production
13 www.demicco.ch

2. Product
Parallel to the development of the series production, direct and indirect sales channels will
be set up to acquire new customers and advanced bookings.
For systems based on the new technology, orders from the Chinese distributor are already
included in the distribution contract with the previous company BMDSys Production GmbH.
The marketing for the new technology has not been started yet.
14 www.demicco.ch

2. Product
APOLLO CXS delivers information about the actual electrophysiological status of the heart
based on the record of the heart‘s magnetic signals.
The new system can become a standard diagnostic tool and can be easily combined with
other diagnostics.
APOLLO CXS provides in the handling of heart patients in the clinical routine a new
parameter that surely in the future will be considered for inclusion in the guidelines of
cardiology.
APOLLO CXS leads to a paradigm change in cardiac diagnostics!
15 www.demicco.ch

2. Product
ADVANTAGES:
Quick and easy: An MFI examination takes maximum 5 minutes including data analysis.
No patient preparation is necessary, not even undressing.
Non-invasive: The sensor system is positioned over the patient‘s chest, it does not touch
the patient!
Side-effect-free: The data acquisition is pure passive, no contrast agents are necessary
and no ionizing radiation is used.
Cost efficient: No helium cooling, room temperature leads to minimum operational costs.
Repeatable: The examination can be repeated as often as required as there are no side
effects. The diagnosis is applicable for all patient groups.
16 www.demicco.ch

2. Product
2.4 Production/production costs, sales prices
Current production costs per system based on the new technology:
348,000 EURO
Production costs considering a rationalized series production (from 2nd
year)
290,000 EURO
Sales prices:
Price per system for direct sales
650,000 EURO
Price per system for sales via distributors:
500,000 EURO
17 www.demicco.ch

2. Product
2.5 Technology
The technology have two key fields:
The management of the environmental noise, obtained
with a intelligent distribution of the load to the
different system component (Shielding, sensor, real‐time
signal processing, software noise compensation)
The Analysis algorithm to extract the clinical relevant
information from the magnetic data.
More information will be given by Dr. Erné
18 www.demicco.ch

3.
Management team
19 www.demicco.ch

3. Management team
3.1 Volker Schall, CEO
Volker Schall is a skilled banker and was able to successfully apply
his knowledge in several production and sales companies in the
sports industry.
Because of his expertise in the sports industry he knows the
demands and problems in this field and thus can take advantage of
the enormous potential of this market.
With his great experience as sales manager he is ideal for the
scopes of marketing and sales of the optical diagnosis systems.
Volker offers the whole necessary commercial and sales-related
know-how for being able to lead BMDSys Optical GmbH towards a
successful future.
20 www.demicco.ch

3. Management team
3.2 Dr. rer. nat. Gertrud Lembke, CTO
Since finishing her studies in physics and her doctorate in 2007, Dr.
rer. nat. Gertrud Lembke (Ms.) was involved in the development of
the optical magnetometers as a scientific employee at the
University Hospital Jena.
Here, she extended her experience in the construction of a
multichannel optical magnetic field sensor system as well as in
simulation and construction of complex coil systems for well
defined magnetic fields.
For her work on this system she received in 2010 the price „Young
Investigator Award“ in the field „instrumentation“ at the
international conference for biomagnetism BIOMAG 2010. She has
the necessary physical know-how for optimizing the system for the
use in clinical routine.
Gertrud is the technical developer from the start of the
company.
21 www.demicco.ch

3. Management team
3.3 Further executive personnel and employees
Heike Kroker-Häge
Heike Kroker-Häge (Ms.) was responsible for
the quality management of the
superconducting MFI systems for a long time
and knows the necessary steps for the
registration of a medical product.
Furthermore, she has great experience as an
executive assistant, in the scope of
administration, national and international
sales, export, import and purchase.
Dr. rer. nat. Reinhard Kürsten
Reinhard Kürsten studied physics in
Hamburg and obtained his doctorate in 2002.
Subsequently, he was employed at the
‚Physikalisch-Technischen Bundesanstalt‘ in
Berlin in the field of biomagnetic diagnostic.
He was responsible for the final assembly
and testing of the present MFI systems as
well as for their installation.
His extensive knowledge regarding the
behavior and treatment of highly permeable
metal plates is of great importance for the
future development.
22 www.demicco.ch

3. Management team
3.3 Further executive personnel and employees
MsC. Yingbin Wu
Yingbin Wu works on the programming of the
data acquisition and analysis software of the
present MFI systems.
His knowledge and experience are of great
importance for the adaption of the present
programming to the optical magnetometers.
Furthermore, Yingbin Wu is responsible for
the contact to a Chinese distributor who
currently sells the helium cooled systems in
China.
Dipl.-Ing. Klaus Brandt
As experienced development engineer in the
field of medical engineering Mr. Brandt was
involved in the whole production process of
the helium cooled MFI systems since 2010.
In addition, as development and construction
engineer, Klaus Brandt is responsible for the
mechanical parts necessary for the operation
of the system.
23 www.demicco.ch

3. Management team
3.4 Advisory board
Professor Dr. Sergio Nicola Erné
Has been involved since 1976 in research
and development in all aspects of the
technology of high sensitive magnetic
measurement for biological and medical
applications.
He was active at the PTB in Berlin, the
University of Ulm,(GE), the University of
Chieti (IT) and the University of Jena (GE).
He had cooperating with Siemens, General
Electric and Atb.
He joined all industrial efforts of BMDSys.
(For more information please see the CV)
Dr. Luigi Carlo De Micco
Luigi joined the company as consultant and
investor in the beginning of 2014. He is an
experienced entrepreneur and investment
banker with a strong background in the
growth development of IT and technology
companies. He did and managed several
IPO’s in European stock exchanges and at
NASDAQ. Today Luigi is the CEO &
president of the De Micco & Friends group
which is represented with more than 200
lawyers, auditors and investment bankers in
Europe.
(For more information please see the CV)
24 www.demicco.ch

4. Market overview
4.1 Target groups
The largest sales potential is in hospitals
and large medical centers that offer heart
diagnostics on the latest state of
technology. APOLLO CXS offers
acquisition, display and analysis of the
magnetic signals of the human heart.
Thus, several large diagnostic sectors in
cardiology can be covered at the same
time, e.g. risk stratification of future life-threatening
arrhythmias and detection of
acute and stress induced ischemia.
The alternative diagnostic methods do
not provide the precision, comfort,
efficiency or a combination of the
mentioned criteria. Some of the
alternatives are invasive and/or put high
side effects to the patient .
Special hospitals,
universities
Large medical
centers
Medical
prevention
Sports centers
Cardiological
hospitals
Cardiologists
Prevention
Sports centers
Sports
organisations
Modern
practices
Direct sales Sales via distributors Admission of health
insurances
Sports Prevention facilities
Medical
26 www.demicco.ch

4. Market overview
4.2 Competitors
AtB, Pescara (Italy) (A)
AtB was founded in 1990 and had co-operations with
the universities of Ulm and Jena for some years. It
carried out orders of the universities and delivered a
system named „Argos 200“ for magnetic heart
measurement to the university of Jena. This
company is not significantly active any more since
2006 and never established an industrial production
of MFI systems. AtB does not offer an optical
technology!
CardioMag Imaging (USA) (B)
Cardiomag sold in the past a 9-channel system for
the measurement of the heart‘s magnetic field with
which acute ischemia in the human heart can be
detected. However, the recording bandwidth was so
small and the noise so high that the system could not
be used for risk stratification based on the QRS
fragmentation. No optical technology available.
Elekta, Stockholm (Sweden) (C)
In a subsidiary of Elekta a system for
electroencephalography (helmet shaped) is
produced and sold. It is not possible to measure
heart signals with this system and thus this product
is no competition to our system. No optical
technology available.
BMP Hamburg (Germany) (D)
In August 2010 the magnetocardiography (MCG)
technology of KRISS was transferred to Biomagnetik
Park GmbH. In January 2012 an MCG system of the
company Biomagnetik Park GmbH was certified as a
new medical device for the diagnose of coronary
heart diseases according to the European Medical
Directive 93/42/EEC. There is no compatible
software for a risk stratification of sudden cardiac
death. No optical technology available.
27 www.demicco.ch

4. Market overview
4.2 Competitors
All systems of competitors are
based on superconductive sensors,
i.e. they require helium cooling for
operation.
Thus, those suppliers are no real
competition for the optical system
of BMDSys Optical GmbH.
The operation without helium is a
unique selling proposition that is
not offered by any competitor and
saves approx. 900 K EURO of
operation costs during 10 years (life
cycle of a SQUID based MFI
system).
Thus, the optical MFI system
APOLLO CXS is unique in the
whole world.
Competitor
A
Competitor
B
Competitor
C
Competitor
D
APOLLO CXS
Price ↑ ↓ ↔ ↑ ↓
Performance ↑ ↓ ↙ ↔ ↑
Regional market
share ↓ ↓ ↓ ↓ ↓
National market
share ↓ ↓ ↓ ↓ ↓
Regional
acceptance ↔ ↔ ↔ ↔ ↑
National
acceptance ↔ ↔ ↔ ↔ ↑
Product range ↔ ↓ ↔ ↗ ↓
Marketing ↔ ↙ → ↔ ↔
Innovation ↔ ↔ ↙ ↔ ↑
Company size ↓ ↑ ↓ ↔ ↔
On the market
since 1990 2005 2000 ‐ 2005 2010 2008
Legend: ↑ very high; ↗ high; ↔ moderate; ↙ low; ↓ very low
28 www.demicco.ch

4. Market overview
4.3 Market potential
The market potential is enormous!
Considering the fact that no
comparable product for heart
diagnostics is available until now,
BMDSys Optical GmbH has the
potential for being a „global
player“ in this segment.
It can be supposed that BMDSys
Optical GmbH first will have a
monopoly position on the global
market with its product.
The developmental edge of
approx. 5 years can hardly be
caught up with even by larger
companies that want to set up a
competition.
600.0 bn
60.0 bn
2.0 bn
75 %
Market capacity global
Market potential
Market volume
Scheduled
market share until 2018
29 www.demicco.ch

5.
Chances and risks
30 www.demicco.ch

5. Chances and risks
Optimum initial situation for investors
BMDSys Optical GmbH is in a classic „next‐ level‐position“.
The management and development team
is well attuned, the main product is ready for market.
The newly founded company is completely free from
encumbrances and can now start with an
appropriate funding.
Contrary to comparable technology companies
where the main part of financial resources had to be
invested in research and development BMDSys
Optical GmbH provides a nearly finished and
market‐ready product.
Chances
 Best product on the market
 Competitive edge can be secured in case of preferably
soonest market entry
 Potential for global player and market leader
 Worldwide high demand
 Existing orders
Risks
 Supply bottleneck at suppliers of applicable material
 Handling of the expected growth
 Copying of the technology by competitors (very difficult)
31 www.demicco.ch

6.
Financial planning
32 www.demicco.ch

6.1 Sales figures
Sales planning P1 P2 P3
Price/system
China & US (Transfer of distribution contract) 500,000,00 € 2 7 16
Channel direct sales 650,000,00 € 0 2 5
Channel distribution 600,000,00 € 0 14 11
Mobile system option 380,000,00 € 2 2 0
Revenues from sales 1,760,000,00 € 14,590,000,00 € 18,170,000,00 €
Maintenance 20,000,00 € 0 80,000,00 € 500,000,00 €
Capital inflow from investors 3,000,000,00 €
Revenues in total 1,760,000,00 € 14,670,000,00 € 18,670,000,00 €
The sales figures of BMDSys Optical GmbH especially depend on the production capacities to be
managed. In case of conservative planning, from 2nd. Year on 25 units, i.e. approximately two
system per month, will be produced if the expected funding will be available. This means a turn over
of already 14,6 mio. EURO. Up from 3th. year the production will be increased to at least 32 units
which means an average turn over of 18,6 mio. EURO.
33 www.demicco.ch

6.2 Cost of materials
Cost of materials P1 P2 P3
Shelter 75,000,00 € 1,650,000,00 € 1,200,000,00 € 1,500,000,00 €
Mu‐Metall 75,000,00 € 1,650,000,00 € 1,200,000,00 € 1,500,000,00 €
Master console and workstation 12,000,00 € 264,000,00 € 192,000,00 € 240,000,00 €
Elektronic hardware 40,000,00 € 880,000,00 € 640,000,00 € 800,000,00 €
Laser 12,000,00 € 264,000,00 € 192,000,00 € 240,000,00 €
Optical sensor 100,000,00 € 2,200,000,00 € 1,600,000,00 € 2,000,000,00 €
Cosmetics und electrical infrastructur 12,000,00 € 264,000,00 € 192,000,00 € 240,000,00 €
Other materials 12,000,00 € 264,000,00 € 192,000,00 € 240,000,00 €
Installation 10,000,00 € 220,000,00 € 160,000,00 € 200,000,00 €
Cost of material / mashine 348,000,00 €
Cost of material in total 7,656,000,00 € 5,568,000,00 € 6,960,000,00 €
The costs of material are calculated proportionally to the sold units. Based on the long delivery time
of up to 3 months for single components, purchasing and financing has to be scheduled accordingly.
34 www.demicco.ch

6.3 Cost of personnel
Cost of personnel P1 P2 P3
Number of employees 18 18 18
CEO 11,000,00 € 132,000,00 € 138,600,00 € 145,200,00 €
CTO 5,900,00 € 70,800,00 € 74,340,00 € 77,880,00 €
Backoffice 5,000,00 € 55,000,00 € 63,000,00 € 66,000,00 €
Software/Analysis 5,900,00 € 70,800,00 € 74,340,00 € 77,880,00 €
Software/ data base 5,900,00 € 70,800,00 € 74,340,00 € 77,880,00 €
QM 5,900,00 € 70,800,00 € 74,340,00 € 77,880,00 €
RealTime Software 5,900,00 € 70,800,00 € 74,340,00 € 77,880,00 €
Medical technics 5,900,00 € 53,100,00 € 74,340,00 € 77,880,00 €
Elektronic 5,900,00 € 53,100,00 € 74,340,00 € 77,880,00 €
Production eng. 5,900,00 € 70,800,00 € 74,340,00 € 77,880,00 €
Produkcion eng. 5,900,00 € 29,500,00 € 74,340,00 € 77,880,00 €
Production assistance 4,200,00 € 37,800,00 € 52,920,00 € 55,440,00 €
Production assistance 2 4,200,00 € 37,800,00 € 52,920,00 € 55,440,00 €
Production assistance3 / Customer ralation 4,200,00 € 50,400,00 € 52,920,00 € 55,440,00 €
Sales‐Rep 1 5,900,00 € 70,800,00 € 74,340,00 € 77,880,00 €
Sales‐Rep 2 5,900,00 € 64,900,00 € 74,340,00 € 77,880,00 €
Costs of personel 1,026,000,00 € 1,283,940,00 € 1,345,080,00 €
The costs for personnel increase with increasing production. For the two founders (CEO and CTO) an
additional performance‐related bonus system should be developed.
35 www.demicco.ch

6.4 Operational costs (without personnel)
Operational costs P1 P2 P3
Staff secondary costs 2% 20,520,00 € 25,678,80 € 26,901,60 €
Fees (COC, associations etc.) 1,500,00 € 18,000,00 € 18,000,00 € 18,000,00 €
Delivery costs 1,000,00 € 12,000,00 € 12,000,00 € 12,000,00 €
Financial costs 1,500,00 € 18,000,00 € 18,000,00 € 18,000,00 €
Recycling 2,000,00 € 24,000,00 € 24,000,00 € 24,000,00 €
Lawyers 4,000,00 € 48,000,00 € 48,000,00 € 48,000,00 €
Accountants 2,500,00 € 30,000,00 € 30,000,00 € 30,000,00 €
Rent 15,000,00 € 120,000,00 € 180,000,00 € 216,000,00 €
Energy 150,00 € 26,250,00 € 32,400,00 € 32,400,00 €
Phone, communication 100,00 € 17,500,00 € 21,600,00 € 21,600,00 €
Internet 500,00 € 6,000,00 € 6,000,00 € 6,000,00 €
Cars 6,000,00 € 72,000,00 € 108,000,00 € 144,000,00 €
Consultants 10,000,00 € 120,000,00 € 120,000,00 € 120,000,00 €
CE + QM 1,500,00 € 18,000,00 € 18,000,00 € 18,000,00 €
Cleaning 1,000,00 € 7,200,00 € 12,000,00 € 24,000,00 €
Marketing 5,000,00 € 60,000,00 € 60,000,00 € 180,000,00 €
Others 5,000,00 € 60,000,00 € 60,000,00 € 60,000,00 €
Insurance 10,000,00 € 120,000,00 € 120,000,00 € 120,000,00 €
Office facilities 2,000,00 € 24,000,00 € 24,000,00 € 24,000,00 €
Exhibitions (4 /year, 2 national, 2 international) 100,000,00 € 0,00 € 400,000,00 € 800,000,00 €
Travel 4,000,00 € 36,000,00 € 96,000,00 € 124,800,00 €
Reporting investor 5,000,00 € 0,00 € 20,000,00 € 20,000,00 €
Movement of company location 50,000,00 € 50,000,00 € 20,000,00 € 0,00 €
Installation costs 8,000,00 € 0,00 € 144,000,00 € 128,000,00 €
Maintenance Laser 700,00 € 8,400,00 € 8,400,00 € 8,400,00 €
Software 10,000,00 € 10,000,00 € 10,000,00 € 10,000,00 €
Patents 20,000,00 € 30,000,00 € 60,000,00 €
Operational costs total 945,870,00 € 1,666,078,80 € 2,294,101,60 €
36 www.demicco.ch

6.5 Investments
Investments P1 P2 P3
IRFA 90,000,00 € 90,000,00 € 0,00 € 0,00 €
High permeable material 90,000,00 € 90,000,00 € 0,00 € 0,00 €
Coil material 10,000,00 € 10,000,00 € 0,00 € 0,00 €
New sensor head holder 25,000,00 € 25,000,00 € 0,00 € 0,00 €
New sensor head 60,000,00 € 60,000,00 € 0,00 € 0,00 €
Non‐magnetic adjustable mattress 20,000,00 € 20,000,00 € 0,00 € 0,00 €
Electronic hardware 100,000,00 € 100,000,00 € 0,00 € 0,00 €
Office equipment 75,000,00 € 60,000,00 € 15,000,00 € 0,00 €
Production equipment 150,000,00 € 75,000,00 € 75,000,00 € 0,00 €
Field testing equipment 70,000,00 € 70,000,00 € 0,00 € 0,00 €
Magnetic test equipment (2x) 40,000,00 € 80,000,00 € 0,00 € 0,00 €
Basic optical equipment 60,000,00 € 60,000,00 € 0,00 € 0,00 €
Forklifts (2x) 10,000,00 € 10,000,00 € 10,000,00 € 0,00 €
Container transport system internally (2x) 100,000,00 € 100,000,00 € 100,000,00 € 0,00 €
Power generation system for 110V / 60Hz (USA) 50,000,00 € 50,000,00 € 0,00 € 0,00 €
Investments total: 900,000,00 € 200,000,00 € 0
For the first operational year only 900K EURO are necessary, with which the whole development
and production process is covered. The previous company invested during it‘s operational time
approx. 8 M. EURO. BMDSys Optical GmbH can proceed with it‘s activities completely
unencumbered.
37 www.demicco.ch

6.6 Cash Flow Overview
Cash Flow P1 P2 P3
Revenues 1,760,000,00 € 14,670,000,00 € 18,670,000,00 €
Costs of materials 7,656,000,00 € 5,568,000,00 € 6,960,000,00 €
Costs of personnel 1,026,000,00 € 1,283,940,00 € 1,345,080,00 €
Operational costs without personnel 945,870,00 € 1,666,078,00 € 2,294,101,00 €
EBITDA: ‐7,867,870,00 € 6,151,982,000,00 € 8,070,899,00 €
Cash Flow accumulated: 812,130,00 € 6,738,111,20 € 14,743,929,60 €
Cash flow: ‐87,870,00 € 5,638,111,20 € 14,543,929,60 €
When calculating conservatively, until the end of the year only a turnover of 1,7 M is achieved that
results from existing orders. But depending on the time of the financing and delivering of
components, within 9‐12 months sales profits can be achieved. The cash flow of the first year
considers already the payment of an investment sum of 10 mio. EURO.
From the second year on (see business plan) the cash flow of the company is positive.
38 www.demicco.ch

6.7 Capital demand
The actual capital demand of the company is 10 mio. EURO.
The capital will be used in the following ways:
- Finishing the series-production readyness of the prototype
APOLLO CXS
- Optimizing the production
- Set up of national and international sales
- National marketing aktivities
- Continuing the health insurance license
- Prefinancing the existing and future orders
39 www.demicco.ch

7.
Offer for investors
40 www.demicco.ch

7.1 Participation
Interested investors can participate directly in the BMDSys Optical
GmbH.
Considering the sales and profit and the enormous market- and
development potential the company today is rated with minimum
32 mio. EURO.
The momentary proprietors offer investors a company share of up
to 33 % for an exceptional price of 10 mio. EURO, which covers
the momentary capital need.
With an committed institutional investor on board it’s possible to get
a further finance by a German government institution (TBG) about
50% of the investors engagement on a loan basis.
41 www.demicco.ch

7.2 Exit strategies
The management teams searches investors for medium and long
term attendance.
The actual business plan was set up for 3 years. From the 4th year
on an industrial production should be established, that covers the
demand. It can be assumed that the company than faces another
developmental step.
Possible exit strategies from the momentary point of view:
- Rebuy of shares through the company owner
- IPO, Reverse Merger
- M&A transaction
42 www.demicco.ch

Further questions?
Please contact us:
Volker Schall
eMail: vs@bmdsysoptical.com
Phone: + 49 261 98279819
Mobile: + 49 151 432 638 01
Dr. Luigi Carlo De Micco
eMail: luigi@demicco.ch
Phone: + 34 871 944 532
Mobile: + 34 637 216 267
Web: www.demicco.ch
43 www.demicco.ch

New business summary of BMDSys Optical investment

Recommended

Recommended

More Related Content

Similar to New business summary of BMDSys Optical investment

Similar to New business summary of BMDSys Optical investment (20)

More from De Micco & Friends Group

More from De Micco & Friends Group (20)

Recently uploaded

Recently uploaded (20)

New business summary of BMDSys Optical investment